Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

23andMe Stock

Q: Can you buy 23andMe stock?

You can no longer buy 23andMestock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

23andme.comHealthcare / Healthcare providers & servicesFounded: 2006Funding to Date: $876.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Learn more about 23andMe IPO

Enterprise Value

Access valuation and stock price for companies like 23andMe before its SPAC.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

23andMe stock FAQs

Can you buy 23andMe stock?

You can no longer buy 23andMe stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy 23andMe stock?

To invest in a private company like 23andMe through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell 23andMe stock?

You can no longer sell stock of 23andMe on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell 23andMe stock?

If you hold private company shares of 23andMe - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your 23andMe stock on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is 23andMe a public company?

No, 23andMe is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is 23andMe’s stock price?

The stock price of 23andMe is $0.67 as of 1/18/24.

What is 23andMe’s stock ticker symbol?

The ticker symbol of 23andMe is ME.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

23andMe investors also invested in these private companies

Fidelity Investments

Zipline, Redwood Materials, Fanatics, Discord, Lime, Diamond Foundry, ThoughtSpot, Fever, Freenome, Hootsuite

Casdin Capital

Formation Bio, Paige, Aledade, LetsGetChecked, FogPharma, Scorpion Therapeutics, Vineti, Asimov, Flare Therapeutics, Septerna

Altimeter Capital

Cerebras, Helion Energy, StockX, Gusto, Ramp, Plaid, Workato, Duetto, Starburst Data, Clumio

Sequoia Capital

Wiz, xAI, Cerebras, Perplexity, Zipline, Graphcore, Hugging Face, Cohesity, Klarna, Stripe

Team

Management Team

Steve Schoch

CFO

Kenneth Hillan, M.B., Ch.B

Head of Therapeutics

Anne Wojcicki

CEO & Co-Founder

Fred Kohler

Vice President, People

Kathy Hibbs JD

Chief Legal & Regulatory Officer

Mike Polcari

Vice President & Chief Architect

Board Members

Patrick Chung

Xfund

Roelof Botha

Sequoia Capital

Anne Wojcicki

23andMe

Neal Mohan

23andMe

Richard Scheller, Ph.D.

Self

Genomeweb 01/18/2022

23andMe Study Associates Gene Locus With COVID-19-Related Loss of Smell, Taste

A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.

Genomeweb 10/29/2021

People in the News: New Appointments at Roswell Biotechnologies, 23andMe, Akoya Biosciences, More

Genomeweb 10/22/2021

23andMe to Acquire Telemedicine Platform Company Lemonaid Health for $400M in Cash, Stock

Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.

The Street 10/22/2021

23andMe Stock Drops on Plan to Buy Health Platform Lemonaid

23andMe shares drop after the consumer genetics company definitively agrees to pay $400 million for health platform Lemonaid.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.